Imcyse was founded by Professor Jean-Marie Saint-Rémy. The original discoveries were made with his team at the Katholic University of Leuven (KUL) and subsequently developed at Imcyse as the technology was optimised and the programs advanced.

The company has continued to develop with the support of investments from key shareholders (including Biogenosis, LSP, Noshaq, SRIW, SFPI, KUL) as well as a number of grants and bursaries from the Walloon Region. In 2021, with the licensing of our Rheumatoid Arthritis program and the acquisition of the IP from the university, Pfizer and LSRP joined as shareholders.

In 2021, the company moved to our own laboratories based in Liege.